Company news
Ucb S.a. (EURONEXT:UCB) news
Ucb S.a. news releases on 6ix. Latest, Sep 30, 2026: UCB : announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating…
Press releases & updates
UCB : announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating hidradenitis suppurativa
September 30, 2026
UCB : data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
September 29, 2026
UCB : receives U.S. FDA Breakthrough Therapy Designation for CIMZIA (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
September 9, 2026
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing
August 31, 2026
UCB : Transparency notification Wellington Management Group LLP
August 31, 2026
Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
August 5, 2026
UCB : Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase
July 30, 2026
UCB : presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026
July 8, 2026
UCB : FASTRAX working session highlights progress in axSpA diagnosis
July 3, 2026
UCB : completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
June 17, 2026
UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
June 9, 2026
UCB - EULAR 2026, Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
June 5, 2026
UCB : New EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels
June 5, 2026
UCB : BIMZELX(bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA
June 3, 2026
UCB : completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science
June 2, 2026
UCB : and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
June 1, 2026
UCB : Financial Reporting Document
May 20, 2026
UCB : Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
May 7, 2026
UCB announces acquisition of IMIDomics Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases
May 4, 2026
UCB : to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
May 3, 2026
UCB : announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
May 1, 2026
UCB : General Meeting of Shareholders 2026
April 30, 2026
UCB : to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
April 17, 2026
UCB - Acquisition of own shares
April 13, 2026
UCB : Acquisition of own shares
April 10, 2026
UCB - Convening Notice to the General Meeting of the Shareholders 2026
March 27, 2026
UCB : Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
March 24, 2026
UCB : Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
March 13, 2026
UCB : and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
March 3, 2026
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
September 10, 2025
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
August 29, 2025
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
August 5, 2025
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
July 8, 2025
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
June 27, 2025
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
June 20, 2025
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
June 17, 2025
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
June 12, 2025
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
June 11, 2025
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
May 19, 2025